Organisation paid for research Program year 2025 Source: CMS Open Payments

CTMD Research

Neither a doctor nor a teaching hospital

Research payments

$3,388,897

24 payments

Through program year 2025, CTMD Research is reported as receiving $3,388,897 in research payments, across 24 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$367,733	4
2024	Research	$476,099	3
2023	Research	$70,807	2
2022	Research	$900,923	4
2021	Research	$1,571,252	10
2020	Research	$2,082	1

Breakdown

Who paid Research payments · program years 2020–2025

Becton, Dickinson and Company $2,474,257 15 payments
Novartis Pharmaceuticals Corporation $914,640 9 payments

Studies the money was for Research payments · program years 2020–2025

Maxmm1 $894,442 2 payments
Veritor Antigen Assay $672,021 2 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $541,499 3 payments
Covid BioSpec $310,074 4 payments
VerFresh $285,032 2 payments
MAX COVID EUA FDA Response $231,902 2 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $134,101 3 payments
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $119,592 1 payment
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $77,264 1 payment
Cor (HT) Mgen $76,180 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.